Bevacizumab and retinal ischemia.
Neubauer
Aljoscha S
AS
Kook
Daniel
D
Haritoglou
Christos
C
Priglinger
Siegfried G
SG
Kampik
Anselm
A
Ulbig
Michael W
MW
Ceklic
Lala
L
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000150:complications; D005451:Fluorescein Angiography; D006801:Humans; D007511:Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008269:Macular Edema / Q000209:etiology; D012171:Retinal Vessels / Q000187:drug effects*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab